Here are the 10-Q quarterly reports from Veradermics, Incorporated (MANE) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow MANE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MANE filings page.
Veradermics, Inc. (MANE), a clinical-stage biopharmaceutical company, reported a $71.7 million net loss for the nine months ended September 30, 2026, versus $48.1 million in the comparable 2025 period. Net cash used in operating activities was $58.6 million, versus $48.0 million. The company has no approved products and expects operating losses to continue.
Cash, cash equivalents and marketable securities totaled $798.4 million as of September 30, 2026; the company expects these resources to cover obligations for at least 12 months from the date the financial statements are available to be issued. In October, it reported that Phase 3 Study 304 met all primary and secondary endpoints among 536 men. At Month 6, average hair-count increases were 28.6 hairs/cm² once daily and 36.4 hairs/cm² twice daily, versus 6.6 with placebo. The study reported no treatment-related serious adverse events or adverse events of special interest of cardiac origin.
In November, Study 302’s continued-treatment group had Month 12 hair-count increases of 43.9 hairs/cm² BID and 29.7 hairs/cm² QD from baseline. The company expects topline results from female Study 306 in the first half of 2027.
Veradermics, Incorporated reported substantially larger operating losses while transforming its balance sheet with major equity financings for the six months ended June 30, 2026. The company remains a late clinical-stage biopharmaceutical business focused on VDPHL01 for pattern hair loss and other dermatology candidates.
Total operating expenses rose to $59.4 million, driven by research and development of $39.5 million and general and administrative costs of $19.9 million, resulting in a net loss of $50.7 million versus $28.0 million a year earlier. Financing activities included a February IPO with net proceeds of $269.1 million, a May follow-on offering raising $414.3 million, and a concurrent private placement of pre-funded warrants adding $28.1 million.
These transactions increased cash, cash equivalents and marketable securities to $819.9 million as of June 30, 2026, compared with $140.3 million at December 31, 2025. Management states this liquidity is expected to meet obligations for at least twelve months, supporting ongoing Phase 2/3 and Phase 3 programs for VDPHL01 and other pipeline assets.
Veradermics, Incorporated reported a net loss of $27.2 million for the three months ended March 31, 2026, as it increased investment in late-stage dermatology programs. Research and development expenses rose to $20.9 million and general and administrative costs reached $8.9 million, reflecting expanded clinical activity and public-company readiness.
The company strengthened its balance sheet with an IPO in February 2026 generating net proceeds of $269.1 million, bringing cash, cash equivalents and marketable securities to $390.8 million as of March 31, 2026. Subsequent May 2026 follow-on and private offerings added $472.0 million in gross proceeds to support development of lead candidate VDPHL01 and its broader dermatology pipeline.